Breast cancer

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 00:49, 18 February 2012 by Michael Benjamin (talk | contribs) (Created page with "==Adjuvant Therapy== ==Metastatic Disease== ===Single agents=== ====Halaven==== *Eribulin (Halaven) 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cy...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Adjuvant Therapy

Metastatic Disease

Single agents

Halaven

  • Eribulin (Halaven) 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle
References
  1. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. Epub 2011 Mar 2. PubMed
  2. Package Insert
Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer&oldid=818"